BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Revenue
Annual & quarterly revenue history · segment & region breakdown
BBIO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBridgeBio Pharma, Inc. trailing twelve-month (TTM) revenue is $0.58B, an increase of 126.26% year-over-year from $0.50B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.50B | +$0.28B | +126.26% |
| 2024-12-31 | $0.22B | +$0.21B | +2285.27% |
| 2023-12-31 | $0.01B | -$0.07B | -88.02% |
| 2022-12-31 | $0.08B | +$0.01B | +11.38% |
| 2021-12-31 | $0.07B | +$0.06B | +745.14% |
| 2020-12-31 | $0.01B | -$0.03B | -79.66% |
| 2019-12-31 | $0.04B | +$0.04B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare BBIO revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income BridgeBio Pharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
BridgeBio Pharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from BridgeBio Pharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BBIO revenue · 4 questionsBBIO's trailing twelve-month (TTM) revenue is $0.58B. That is an increase of 126.26% year-over-year from $0.50B in FY2025.
▸ Source: FMP · BridgeBio Pharma, Inc. SEC filings · GAAP · BridgeBio Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026